[Comment. Higher safety for patients and lower costs for society].
García-Altés
Anna
A
Agència de Salut Pública de Barcelona, Fundación Instituto de Investigación en Servicios de Salud, Barcelona, España.
D001241:Aspirin / Q000009:adverse effects* / Q000191:economics; D003365:Costs and Cost Analysis; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000191:economics; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000191:economics; D012449:Safety
D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D009853:Omeprazole; D001241:Aspirin